Similarly, 48.5% of our cohort showed a GH peak at the GST of less than 5.8 μg/L, 94.4% of the OS-GHD group (82.3% of which had brain tumors), 74.3% of the OM-GHD group (84.6% of which were CCS or underwent CSI or TBI), and 9% of the I-GHD group. Here, GH1 is linked to ocular melanoma.